The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
End-stage heart failure (HF) is a progressive illness with a mortality rate similar to most
advanced cancers.Roughly 5% of patients with HF have end-stage disease that is refractory to
medical therapy (stage D heart failure). When patients reach this point in their disease, the
only treatments known to prolong life are cardiac transplantation or left ventricular assist
devices. In patients who do not qualify for these options, or elect a palliative approach,
inotropes are frequently used to improve hemodynamics through an increase in cardiac output
and reduction in filling pressures. While inotropes provide profound symptomatic relief,
these benefits are accompanied by significant risks of progressive adverse cardiac
remodeling, arrhythmias, and sudden death. There is, therefore, an urgent need to develop
strategies to reduce the dose or duration of inotrope use in the management of patients with
stage D of HF.